Treating organ inflammation
LSALT Peptide (Metablok) is designed to target acute organ inflammation in the lungs, liver and kidneys.
Get stock information, press releases, financials and management’s discussion and analysis.
Arch Biopartners Science
Learn about the company’s medical trials, clinical research and journal publications.
Find out why Arch is distinct – our approach, and the team behind our science.
Developing drugs to prevent inflammation and organ injury
Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and organ injury.
DEVELOPING A pipeline of patented new drug candidates that;
- inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
- are relevant for multiple indications where organ inflammation is an unmet problem with no effective treatments in the market today.
Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Find out more about the Company, our focus and the fundamentals that make Arch unique.
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide
April 18, 2023 07:10 ET | Source: Arch Biopartners TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia. LSALT peptide is the Company’s lead drug candidate for treating ...
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
March 23, 2023 07:00 ET | Source: Arch Biopartners TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program. LSALT peptide ...
Find out about the company’s recent advancements, new patents, corporate filings, information for investors and all progress updates on active clinical trials.
- Browse all of the company’s material news releases.
- Read the latest releases when they are published here or via email by subscribing to email alerts and news.
Arch Biopartners key stock indicators.
The Stock Performance page displays current and historical data for both of the Arch Biopartners symbols on the TSX Venture Exchange in Canada and the OTCQB Venture Exchange in the USA.
Please be sure to subscribe for email updates when the company issues news releases and to receive announcements of new scientific data and company events and presentations.
The company’s reports and filings include current filings and an archive for investors and the public to use for research and review:
- Management Discussion and Analysis (MD&A)
- Quarterly and Year-End Financial Statements
- Forms of Proxy, Management Information Circulars (MIC) and Voter Instruction Forms,
- Material Change Reports
- Other SEDAR filings and certifications
View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .
Developing select technologies
Arch Biopartners key technologies, scientists, publications and ongoing trials.
LSALT Peptide (Metablok), is the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
About LSALT Peptide
The pandemic accelerated the company’s drug development plans and has shortened the path toward drug approval and commercialization. Beyond treating inflammation in COVID-19 patients, Arch expects in future that LSALT Peptide will be developed to target organ inflammation in other applications such as cardiac surgery associated kidney injury (AKI).
- LSALT Peptide is the first novel therapeutic to join the ongoing Canadian Treatments for COVID-19 (CATCO) Phase III trial
- In 2020 and 2021, Arch completed a Phase II Trial to investigate LSALT Peptide’s efficacy in the prevention of multiple organ injuries in patients with COVID-19 with patient dosing in the United States, Canada and Turkey.
- Arch scientists’ 2019 publication in the journal Cell, and subsequent research and development has identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. The same, ongoing work also established DPEP1 to be the target of LSALT Peptide, the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
An experienced group of scientists working together to develop the Arch science platforms.
Science and Research Teams
- Current work on LSALT Peptide is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D. (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D., Dr. Paul Beck and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director), who are primarily based at the University of Calgary.
- The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D., Jennifer Rahn B Sc., M Sc. and their colleague Dr. Paul Kubes at the University of Calgary.
The Arch science team also includes:
- Dr. Randall Irvin Ph. D., Dr. Dongyang Li Ph. D. and Dr. Elisabeth Davis Ph. D. at the University of Alberta, whose work on the BORG Peptide is not currently under commercial development.
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
- Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
- AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
- BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
- Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors